Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loratadine in Lymphangioleiomyomatosis (LORALAM)
NCT05190627Phase 2Unknown
- Sponsor
- Bellvitge Institute for Biomedical Research
- Start
- Nov 2021
- Primary completion
- Dec 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of loratadine in lymphangioleiomyomatosis (LAM), sponsored by Bellvitge Institute for Biomedical Research. Status: unknown.
02
Drugs
loratadine
03
Conditions
lymphangioleiomyomatosis (LAM)
Beyond the preview
Go deeper on NCT05190627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05190627.